CStone Pharmaceuticals
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Lorlatinib NCT05297890 |
P2 | Active, not recruiting | Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer | 70 | 2023-12-26 |
| Nofazinlimab (CS1003)+Lenvatinib NCT04194775 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 534 | 2025-06-18 (+24 mo) |
| CS2009 NCT06741644 |
P1/2 | Recruiting | Advanced Solid Tumors | 800 | 2027-01 |
| CS5006 NCT07938814 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 310 | 2029-07 |
| Sugemalimab NCT05700448 |
P3 | Not yet recruiting | Extranodal NK/T-cell Lymphoma | 150 | 2029-12 (+38 mo) |